Drug
Trospium clinical trials
Includes 27 studies of Trospium chloride.
- studies test it
- 48
- open now
- 27
- in phase 3
- 29
- first study started
- 2009
Keep track of what changes. Save the trospium studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Combined with it in one product
- KarXT
- 18
Studies by the year they started
47 studies that test it; most in 2025 (15); 1 more planned to start later
| Year | Studies |
|---|---|
| 2009 | 3 |
| 2010 | 2 |
| 2013 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2020 | 3 |
| 2021 | 4 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 15 |
| 2026 | 8 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 2
- Phase 3
- 29
- Phase 4
- 10
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 41 · Other 7
Bristol-Myers Squibb (17) · Karuna Therapeutics, Inc., a Bristol Myers Squibb company (13) · Karuna Therapeutics (6) · Allergan (5) · Becky Clarkson (1) · University of North Carolina, Chapel Hill (1) · European Group for Research In Schizophrenia (1) · Vanguard Research Group (1)
Often tested with
Tested in the same studies.
Xanomeline (39) · Omeprazole (1) · Metformin (1) · Tamsulosin (1)
Studies
Open first, then newest update. How each study uses trospium is read from its arms, and is right about nine times in ten.
Testing it · 48
- A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I DisorderRecruitingPhase 3Bristol-Myers SquibbNCT06951698Written as KarXT
- A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)RecruitingPhase 3Bristol-Myers SquibbNCT06951711Written as KarXT
- A Study to Evaluate the Effect of KarXT on Urological SafetyRecruitingPhase 4Bristol-Myers SquibbNCT07221877Written as Xanomeline/trospium chloride
- A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)RecruitingPhase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT06126224Written as KarXT
- Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)RecruitingPhase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT05980949Written as KarXT
- A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)RecruitingPhase 3Bristol-Myers SquibbNCT06937229Written as KarXT
- A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)RecruitingPhase 3Bristol-Myers SquibbNCT07011732Written as Xanomeline/Trospium Chloride Capsule
- A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult ParticipantsRecruitingPhase 1Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT07204418Written as Xanomeline/ Trospium Chloride
- A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)RecruitingPhase 3Bristol-Myers SquibbNCT06976203Written as KarXT
- A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's DiseaseRecruitingPhase 3Bristol-Myers SquibbNCT07011745Written as Xanomeline/Trospium Chloride Capsule
- A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's DiseaseRecruitingPhase 3Bristol-Myers SquibbNCT06976216Written as KarXT
- A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)RecruitingPhase 3Bristol-Myers SquibbNCT07288567Written as KarXT
- A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum DisorderNot yet recruitingPhase 3Bristol-Myers SquibbNCT07285798Written as KarXT
- Relapse Prevention Trial Evaluating KarXT Treatment in SchizophreniaRecruitingPhase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT07686263Written as Xanomeline/Trospium Chloride
- A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)RecruitingPhase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT06585787Written as KarXT
- A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)RecruitingPhase 3Bristol-Myers SquibbNCT06929273Written as KarXT
- A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXTRecruitingPhase 1Bristol-Myers SquibbNCT07061288Written as KarXT
- A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With AutismNot yet recruitingPhase 3Bristol-Myers SquibbNCT07284745Written as KarXT
- A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)RecruitingPhase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT05511363Written as KarXT
- A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, Explore the Effect of Food After Multiple Doses of Selected Prototypes, and Evaluate Alternative Formulations of KarX and KarXT Following Single and Multiple Ascending DosesRecruitingPhase 1Bristol-Myers SquibbNCT07063342Written as Xanomeline/Trospium Chloride Capsule
See all 48 studies that test trospium →
Given in every arm · 5 — trospium is usual care beside what is tested
- Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy VolunteersRecruitingPhase 4Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT07681076Written as KarXT
- A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and AdolescentsRecruitingPhase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT07424404Written as KarXT
- A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and DigoxinCompletedPhase 1Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT07118215Written as KarXT
- A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy ParticipantsCompletedPhase 1Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT06729970Written as Xanomeline/Trospium Chloride
- Safety, Tolerability, and Pharmacokinetics of KarXT and Dual-burst Release of Xanomeline With Immediate-release Trospium Chloride in Adolescents With Psychiatric DisordersCompletedPhase 1Bristol-Myers SquibbNCT06853171Written as KarXT
As the comparator · 2 — what is tested is compared with trospium
- Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of FallsCompletedEarly Phase 1The University of Texas Medical Branch, GalvestonNCT05880862Written as Trospium Chloride
- Anticholinergic vs. Botox Comparison StudyCompletedPhase 3NICHD Pelvic Floor Disorders NetworkNCT01166438Written as Trospium chloride
Codes
What other systems call trospium · ClinicalTrials.gg INT017974
- UNII (FDA) T4Y8ORK057TROSPIUMConfirmed FDA, Wikidata
- RxNorm 236778Confirmed FDA, Wikidata
- Wikidata Q513396trospiumConfirmed FDA, Wikidata
- NCI Thesaurus C78080TrospiumOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | T4Y8ORK057 | TROSPIUM | Confirmed FDA, Wikidata |
| RxNorm | 236778 | — | Confirmed FDA, Wikidata |
| Wikidata | Q513396 | trospium | Confirmed FDA, Wikidata |
| NCI Thesaurus | C78080 | Trospium | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.